HONG KONG, 26 October, 2021 – Zhaoke Ophthalmology Limited (“Zhaoke Ophthalmology” or the “Company”, SEHK: 6622), a leading ophthalmic pharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapies that address significant unmet medical needs in China, is pleased to announce that it has appointed PharmaLogic Development, Inc. (“PharmaLogic”) as a Regulatory Consultant to evaluate the Company’s Asian pipeline products for potential development in North America.

PharmaLogic brings over 30 years of service in global pharmaceutical and biomedical industries through the drug development and approval process. PharmaLogic has deep expertise in strategic planning, resource optimization, clinical, and regulatory requirements from candidate selection through to new drug application (NDA) and marketing support. PharmaLogic’s strong relationship and experience with the United States Food and Drug Administration (FDA), combined with the scientific rigor and innovative vision of Zhaoke Ophthalmology will benefit even more patients with eye diseases.

PharmaLogic’s previous consultations resulted in over 50 products approved in numerous markets in a wide range of therapies. The ophthalmic products that PharmaLogic has provided support for include therapies for dry eye disease, glaucoma, bacterial and viral infections, and macular degeneration. PharmaLogic provides personalized, science-based consultation, from early stage trials to approvals and beyond, in partnership with handpicked accomplished professionals with extensive experience in niche areas of medicine.

Dr. Li Xiaoyi (Benjamin), Chairman of the Board, Executive Director and CEO of Zhaoke Ophthalmology, said, “Visual health is incredibly important for everyone. At Zhaoke Ophthalmology, we strive to harness scientific rigor to develop treatments that address the major eye conditions affecting both the front and back of the eye. Thanks to our partnership with PharmaLogic, we can now bring our self-developed innovative drugs to the US market, transforming visual health for patients all around the world.”

“We are pleased to have to the opportunity to work with Zhaoke Ophthalmology in the potential globalization of their science,” says Gary D. Novack, Ph.D., D.A.B.C.P, F.A.C.C.P, President and Founder of PharmaLogic. “It is collaborations with companies such as Zhaoke that PharmaLogic has the opportunity to move new treatments forward to close treatment gaps so clinicians may offer better treatment outcomes. We are excited to embark on this partnership and further Zhaoke’s US footprint.”